



(51) International Patent Classification:
A61K 35/761 (2015.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/EP2018/064524

(22) International Filing Date:
01 June 2018 (01.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1708778.4 01 June 2017 (01.06.2017) GB
1708779.2 01 June 2017 (01.06.2017) GB

(71) Applicant: **PSIOXUS THERAPEUTICS LIMITED**
[GB/GB]; PsiOxus House, 4-10 The Quadrant, Barton Lane,
Abingdon, Oxfordshire OX14 3YS (GB).

(72) Inventors: **CHAMPION, Brian**; PsiOxus Therapeutics
Ltd, PsiOxus House 4-10 The Quadrant, Barton Lane,
Abingdon Oxfordshire OX14 3YS (GB). **BROMLEY,
Alice, Claire, Noel**; PsiOxus Therapeutics Ltd, PsiOxus
House 4-10 The Quadrant, Barton Lane, Abingdon Oxon
OX14 3YS (GB). **BESNEUX, Mathieu**; PsiOxus Ther-

apeutics Ltd, PsiOxus House 4-10 The Quadrant, Barton
Lane, Abingdon Oxon OX14 3YS (GB).


(74) Agent: **HAMBLETON, Bernadette Angelina**; Sterling IP
LTD, Orion House Bessemer Road, Welwyn Garden City
Hertfordshire AL7 1HH (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ONCOLYTIC VIRUS AND METHOD

Figure 29



(57) Abstract: An oncolytic virus (for example a replication competent virus) comprising a transgene cassette encoding an anti-CD40 antibody or binding fragment thereof, wherein the transgene cassette comprises an amino acid sequence given in SEQ ID NO: 12 or a sequence at least 95% identical thereto (such as 96, 97, 98 or 99% identical thereto), in particular a cassette of SEQ ID NO: 12; pharmaceutical compositions comprising the same, methods of preparing said oncolytic virus and compositions and use of the oncolytic virus or composition in treatment, in particular in the treatment of cancer. Also provided is the treatment of a patient population characterised as having a cancer expressing CD40, in particular a cancer over expressing CD40, with a therapy according to the present disclosure.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))